medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-10-47-50medalphabet-3161Research ArticleСтатьиОсобенности течения и распространенности СOVID-19 среди онкологических пациентов в разных странахFeatures of course and prevalence of COVID-19 among cancer patients in different countrieshttps://orcid.org/0000-0003-4341-6017ЮлдашеваН. О.YuldashevaN. O.

Юлдашева Наталия Олеговна, врач-онколог. 

г. Уфа

 Yuldasheva Natalia O., oncologist.

Ufa

https://orcid.org/0000-0002-9618-1664СакаеваД. Д.SakaevaD. D.

 Сакаева Дина Дамировна, д. м. н., проф. 

г. Уфа

Sakaeva Dina D., DM Sci (habil.), professor

 Ufa

https://orcid.org/0000-0002-6403-5945КунафинаР. И.KunafiaR. I.

Кунафина Регина Ириковна, зав. онкологическим отделением противоопухолевой лекарственной терапии № 1.

 г. Уфа

Kunafia Regina I., head of Oncological Dept of Antitumor Drug Therapy No. 1.

Ufa

ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава РоссииРоссияBashkir State Medical UniversityRussian FederationФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России,РоссияBashkir State Medical UniversityRussian Federation202329062023010Диагностика и онкотерапия (1)4750Copyright © Юлдашева Н.О., Сакаева Д.Д., Кунафина Р.И., 20232023Юлдашева Н.О., Сакаева Д.Д., Кунафина Р.И.Yuldasheva N.O., Sakaeva D.D., Kunafia R.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3161Введение

Введение. SARS-CoV-2 и вызванное им заболевание COVID-19 стали причиной пандемии, которая раз и навсегда изменила всю жизнь человечества. В первые месяцы ввиду отсутствия достоверных данных об этом вирусе специалисты не могли даже предположить, как эта ситуация отразится на онкопациентах. По мере накопления опыта работы с этими пациентами в условиях пандемии COVID-19 в медицинских изданиях начали появляться статьи, обобщающие информацию о заболеваемости новой коронавирусной инфекцией (НКИ) и ее течении у онкологических больных. Актуальная информация по этой теме представлена в данном обзоре.

Цель исследования

Цель исследования. Изучение распространенности и особенностей течения COVID-19 на основе анализа актуальных научных публикаций на данную тему.

Результаты

Результаты. Течение COVID-19 зависит от многих факторов, среди которых – возраст, пол, коморбидность, статус ECOG, недавно проведенная цитотоксическая химиотерапия, тип солидной опухоли.

Выводы

Выводы. Ввиду отсутствия в России регистра учета заболеваемости COVID-19 у онкопациентов нет полного понимания, как протекает опухолевый процесс после выздоровления от НКИ. Это требует дальнейшего исследования и глубокого анализа.

Relevance. SARS-CoV-2 and the disease it caused, COVID-19, became the reason of pandemic that changed the entire life of mankind once and for all. In the fist months, due to the lack of reliable data on this virus, experts could not even imagine how this situation would affect cancer patients. With the accumulation of experience in working with these patients in the conditions of the COVID-19 pandemic, articles summarizing information about the incidence of new coronavirus infection (NCI) and its course in cancer patients began to appear in medical publications. Up-to-date information on this topic is presented in this review.Target. The study of the prevalence and features of the course of COVID-19 based on the analysis of current scientifi publications on this topic.Results. The course of COVID-19 depends on many factors, including age, gender, comorbidity, ECOG status, recent cytotoxic chemotherapy, and the type of solid tumor.Conclusions. Due to the absence of a register of the incidence of COVID-19 in Russia, cancer patients do not have a complete understanding of how the tumor process proceeds after recovery from NCI. This requires further research and in-depth analysis.

новая коронавирусная инфекцияонкологические пациентызаболеваемость COVID-19смертность.new coronavirus infectioncancer patientsCOVID-19 morbiditymortality.ReferencesMoujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020; 150: 1–9. https://doi:10.1016/j.critrevonc.2020.102972Moujaess E, Kourie HR, Ghosn M. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. Crit Rev Oncol Hematol. 2020; 150: 1–9. https://doi:10.1016/j.critrevonc.2020.102972Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020; 17 (3): 519–527. https://doi: 10.20892/j.issn.2095–3941.2020.0289Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020; 17 (3): 519–527. https://doi: 10.20892/j.issn.2095–3941.2020.0289Madan A, Siglin J, Khan A. Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med. 2020; 9 (24): 9205–9218. https://doi: 10.1002/cam4.3534Madan A, Siglin J, Khan A. Comprehensive review of implications of COVID-19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic. Cancer Med. 2020; 9 (24): 9205–9218. https://doi: 10.1002/cam4.3534Gulati S, Muddasani R, Gustavo Bergerot P, Pal SK. Systemic therapy and COVID 19: Immunotherapy and chemotherapy. Urol Oncol. 2021; 39 (4): 213–220. https://doi:10.1016/j.urolonc.2020.12.022Gulati S, Muddasani R, Gustavo Bergerot P, Pal SK. Systemic therapy and COVID 19: Immunotherapy and chemotherapy. Urol Oncol. 2021; 39 (4): 213–220. https://doi:10.1016/j.urolonc.2020.12.022Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M, Toraih EA, Saba N, Safah H, Duchesne J, Kandil E. C 6Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: Risk, clinical features, and management. Cancer Biol Med. 2020; 17 (3): 519–527. https://doi:10.20892/j.issn.2095–3941.2020.0289Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M, Toraih EA, Saba N, Safah H, Duchesne J, Kandil E. C 6Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: Risk, clinical features, and management. Cancer Biol Med. 2020; 17 (3): 519–527. https://doi:10.20892/j.issn.2095–3941.2020.0289Strang P, Hedman C, Adlitzer H, Schultz T. Dying from cancer with COVID-19: Age, sex, socio-economic status, and comorbidities. Acta Oncol. 2021; 60 (8): 1019–1024. https://doi:10.1080/0284186X.2021.1934536Strang P, Hedman C, Adlitzer H, Schultz T. Dying from cancer with COVID-19: Age, sex, socio-economic status, and comorbidities. Acta Oncol. 2021; 60 (8): 1019–1024. https://doi:10.1080/0284186X.2021.1934536Ullgren H, Camuto A, Rosas S, Pahnke S, Ginman B, Enblad G, Glimelius I, Fransson P, Friesland S, Liu LL. Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: A Swedish cohort study. Acta Oncol. 2021; 60 (11): 1459–1465. https://doi:10.1080/02841 86X.2021.1958005Ullgren H, Camuto A, Rosas S, Pahnke S, Ginman B, Enblad G, Glimelius I, Fransson P, Friesland S, Liu LL. Clinical characteristics and factors associated with COVID-19-related death and morbidity among hospitalized patients with cancer: A Swedish cohort study. Acta Oncol. 2021; 60 (11): 1459–1465. https://doi:10.1080/02841 86X.2021.1958005Cavalcanti IDL, Soares JCS. Impact of COVID-19 on cancer patients: A review. Asia Pac J Clin Oncol. 2021; 17 (3): 186–192. https://doi:10.1111/ajco.1 3445Cavalcanti IDL, Soares JCS. Impact of COVID-19 on cancer patients: A review. Asia Pac J Clin Oncol. 2021; 17 (3): 186–192. https://doi:10.1111/ajco.1 3445Kuderer, Nicole M et al. Clinical impact of COVID-19 on patients with cancer (CCC 19): A cohort study. The Lancet. 2020; 10241: 1907–1918. https://doi:10.1016/S 0140–6736(20)31187–9Kuderer, Nicole M et al. Clinical impact of COVID-19 on patients with cancer (CCC 19): A cohort study. The Lancet. 2020; 10241: 1907–1918. https://doi:10.1016/S 0140–6736(20)31187–9CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (12): 343–346. https://doi:10.15585/mmwr.mm6912e2CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (12): 343–346. https://doi:10.15585/mmwr.mm6912e2Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and Cancer Consortium. Annals of Oncology. 2021; 32 (6): 787–800. https://doi:10.1016/j.annonc.2021.02.024Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: A report from the COVID-19 and Cancer Consortium. Annals of Oncology. 2021; 32 (6): 787–800. https://doi:10.1016/j.annonc.2021.02.024Zylberman M, Díaz-Couselo FA, Irrazabal C, Flagel S, Custidiano R, Racciopi A, Nicolini C, Bachetti P, Rébora J, Manzano N, Tavella M, Valle S, Noro L, Halac S, Cassal E, Paganini L, Aguirre M, Dictar M. Evolución clínica de pacientes internados con cáncer e infección por COVID-19 [Clinical outcomes in cancer patients hospitalized with COVID-19]. Medicina (B Aires). 2021; 81 (5): 695–702.Zylberman M, Díaz-Couselo FA, Irrazabal C, Flagel S, Custidiano R, Racciopi A, Nicolini C, Bachetti P, Rébora J, Manzano N, Tavella M, Valle S, Noro L, Halac S, Cassal E, Paganini L, Aguirre M, Dictar M. Evolución clínica de pacientes internados con cáncer e infección por COVID-19 [Clinical outcomes in cancer patients hospitalized with COVID-19]. Medicina (B Aires). 2021; 81 (5): 695–702.Фатеева А. В. COVID-19 у онкологических пациентов в Приморском крае: заболеваемость и летальность. Тихоокеанский медицинский журнал. 2020; 4 (82): 5–9. Fateeva A. V. COVID-19 in cancer patients in Primorsky Krai: Morbidity and mortality. Pacifi Medical Journal. 2020; 4 (82): 5–9.Фатеева А. В. COVID-19 у онкологических пациентов в Приморском крае: заболеваемость и летальность. Тихоокеанский медицинский журнал. 2020; 4 (82): 5–9. Fateeva A. V. COVID-19 in cancer patients in Primorsky Krai: Morbidity and mortality. Pacifi Medical Journal. 2020; 4 (82): 5–9.Одилов А. А., Волков А. В., Цимбалист Н. С., Бабиченко И. И. Частота онкологических заболеваний среди 397 пациентов, умерших от COVID-19. Злокачественные опухоли. 2020; 3S 1: 129–130.Одилов А. А., Волков А. В., Цимбалист Н. С., Бабиченко И. И. Частота онкологических заболеваний среди 397 пациентов, умерших от COVID-19. Злокачественные опухоли. 2020; 3S 1: 129–130.Odilov A. A., Volkov A. V., Zimbalist N. S., Babichenko I. I. Incidence of cancer among 397 patients who died from COVID-19. Malignant Tumors. 2020; 3S 1: 129–130.Odilov A. A., Volkov A. V., Zimbalist N. S., Babichenko I. I. Incidence of cancer among 397 patients who died from COVID-19. Malignant Tumors. 2020; 3S 1: 129–130.Каприн А. Д., Хороненко В. Э., Захаренкова Ю. С., Гамеева Е. В. Опыт лечения онкологических больных в условиях пандемии COVID-19. Анестезиология и реаниматология. 2021; 2: 117–123. https://doi.org/10.17116/anaesthesiology2021021117Каприн А. Д., Хороненко В. Э., Захаренкова Ю. С., Гамеева Е. В. Опыт лечения онкологических больных в условиях пандемии COVID-19. Анестезиология и реаниматология. 2021; 2: 117–123. https://doi.org/10.17116/anaesthesiology2021021117Kaprin A. D., Khoronenko V. E., Zakharenkova Yu.S., Gameeva E. V. Experience in the treatment of cancer patients during the COVID-19 pandemic. Anesthesiology and Resuscitation. 2021; 2: 117–123. https://doi.org/10.17116/anaesthesiology2021021117Kaprin A. D., Khoronenko V. E., Zakharenkova Yu.S., Gameeva E. V. Experience in the treatment of cancer patients during the COVID-19 pandemic. Anesthesiology and Resuscitation. 2021; 2: 117–123. https://doi.org/10.17116/anaesthesiology2021021117

The authors declare that there are no conflicts of interest present.